On May 17, 2026, two advocacy groups announced their intention to pursue legal action against the U.K. government regarding a new pharma trade agreement with the U.S.
The groups are specifically focused on regulations that they believe are central to the trade deal and are calling for their revocation.
They have urged the government to reconsider its current stance, emphasizing the potential legal consequences if their demands are not met.